BTAIのチャート
BTAIの企業情報
| symbol | BTAI |
|---|---|
| 会社名 | BioXcel Therapeutics Inc （バイオエクセル・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 BioXcel Therapeutics Inc. is a clinical stage biopharmaceutical company that is focused on the development of drugs for psychiatric disorders and rare cancers. The Company uses novel artificial intelligence (AI) for drug re-innovation processes of approved product candidates to identify new therapeutic indices. Its principal clinical development programs are BXCL501 and BXCL701. BXCL501 is a sublingual thin film formulation of dexmedetomidine (Dex) designed for the acute treatment of agitation resulting from neurological and psychiatric disorders. BXCL701 is an immuno-oncology agent designed for the treatment of prostate and pancreatic cancer. バイオエクセル・セラピュ―ティクスは米国のバイオ医薬品企業。臨床段階で、神経系および免疫腫瘍の分野で新規の人工知能ベ―スの医薬品開発に従事する。同社は撹拌の緊急治療薬BXCL501、前立腺がんおよびすい臓がんの免疫治療薬BXCL701、神経障害に起因する症状の治療薬BXCL502を開発する。本社所在地はコネチカット州ブランフォ―ド。 BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. BioXcel's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BioXcel's two most advanced clinical development programs are BXCL501, an investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine for the treatment of agitation and opioid withdrawal symptoms, and BXCL701, an investigational, orally administered, systemic innate immunity activator in development for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. |
| 本社所在地 | 555 Long Wharf Drive New Haven CT 06511 USA |
| 代表者氏名 | Peter Mueller ピーターミューラー |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 203-643-8060 |
| 設立年月日 | 42795 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2018年 |
| 従業員数 | － |
| url | www.bioxceltherapeutics.com |
| nasdaq_url | https://www.nasdaq.com/symbol/btai |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -10.97000 |
| 終値（lastsale） | 6.7455 |
| 時価総額（marketcap） | 105537023.7975 |
| 時価総額 | 時価総額（百万ドル） 105.76390 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 55.41490 |
| 当期純利益 | 当期純利益（百万ドル） -10.75300 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 BioXcel Therapeutics Inc revenues was not reported. Net loss increased from $1.1M to $7.3M. Higher net loss reflects Research and development increase from $645K to $4.7M (expense) General and administrative increase from $449K to $2.8M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.07 to -$0.57. |
BTAIのテクニカル分析
BTAIのニュース
BioXcel Therapeutics to Report Third Quarter 2022 Financial Results on November 10, 2022 2022/10/27 11:00:00 GlobeNewswire
NEW HAVEN, Conn., Oct. 27, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its third quarter 2022 financial results on Thursday, November 10, 2022 before the open of the U.S. financial markets. BioXcel Therapeutics’ management team will also host a conference call and webcast at 8:30 AM ET to discuss the Company’s financial results and to provide a general business update.
Is the BioXcel Therapeutics Inc. (NASDAQ:BTAI) stock an investment opportunity? 2022/10/20 18:16:00 US Post News
BioXcel Therapeutics Inc. (BTAI)’s stock has witnessed a price hike of 6.76% from the previous close with its current price standing at $11.05. Its current price is -69.72% under its 52-week high of $36.49 and 25.64% more than its 52-week low of $8.80. Based on the past 30-day period, the stock price is -15.82% below […]
BioXcel Therapeutics to Host IGALMI Commercial Day on October 18, 2022 2022/10/05 11:00:00 Wallstreet:Online
NEW HAVEN, Conn., Oct. 05, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will host a Commercial Day presentation for the investment community to provide an update on its recently launched product, IGALMI (dexmedetomidine)
BioXcel Therapeutics (BTAI) Investor Presentation - Slideshow (NASDAQ:BTAI) 2022/09/13 14:18:39 Seeking Alpha
The following slide deck was published by BioXcel Therapeutics, Inc.
BioXcel Therapeutics to Participate at the H.C. Wainwright 24th Annual Global Investment Conference 2022/09/07 11:00:18 BioXcel Therapeutics
NEW HAVEN, Conn., Sept. 07, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., Founder and
BioXcel Therapeutics Inc Shares Close the Day 12.3% Higher - Daily Wrap 2022/01/04 11:03:44 Kwhen Finance
BioXcel Therapeutics Inc (BTAI) shares closed today 12.3% higher than it did at the end of yesterday. The stock is currently up 12.3% year-to-date, down 50.6% over the past 12 months, and up 107.0% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $22.94 and as low as $19.66 this week.Shares closed 66.3% below its 52-week high and 22.0% above its 52-week low.Trading volume this week was 59.0% higher than the 10-day average and 56.6% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.4. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.
Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and beats it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance over the past 12 months lags the peer average by 62.6%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
BioXcel Therapeutics Initiates Pivotal Phase 3 Program of BXCL501 for Acute Treatment of Agitation in Patients with Alzheimers Disease 2021/12/15 12:00:00 Intrado Digital Media
Two Phase 3 studies to enroll a total of 300 patients in assisted living or residential facilities and nursing homes to evaluate the safety and efficacy of BXCL501
BTAI: PDUFA Date for BXCL501 Extended to April 5, 2022 2021/12/07 12:30:42 Business Insider Markets
By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update FDA Review of BXCL501 Extended to April 5, 2022 On December 1, 2021, BioXcel Therapeutics, Inc. (NASDAQ:
BTAI: Preparations Underway for Commercial Launch of BXCL501; PDUFA Date of Jan. 5, 2022 2021/12/05 09:11:13 Business Insider Markets
By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update PDUFA Data of Jan. 5, 2022 for BXCL501; MAA Filing Expected in 1H22 In May 2021, BioXcel Therapeutics, Inc. (NASDAQ:
BioXcel Therapeutics Inc. (NASDAQ:BTAI) Decline -10.90%, More Rally Possible 2021/12/02 15:30:00 Marketing Sentinel
In last trading session, BioXcel Therapeutics Inc. (NASDAQ:BTAI) saw 1.0 million shares changing hands with its beta currently measuring 0.94. Company’s recent per share price level of $20.43 trading at -$2.5 or -10.90% at ring of the bell on the day assigns it a market valuation of $561.62M. That closing price of BTAI’s stock is … BioXcel Therapeutics Inc. (NASDAQ:BTAI) Decline -10.90%, More Rally Possible Read More »
BTAI: PDUFA Date for BXCL501 Extended to April 5, 2022 2021/12/07 12:30:42 Business Insider Markets
By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update FDA Review of BXCL501 Extended to April 5, 2022 On December 1, 2021, BioXcel Therapeutics, Inc. (NASDAQ:
BTAI: Preparations Underway for Commercial Launch of BXCL501; PDUFA Date of Jan. 5, 2022 2021/12/05 09:11:13 Business Insider Markets
By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update PDUFA Data of Jan. 5, 2022 for BXCL501; MAA Filing Expected in 1H22 In May 2021, BioXcel Therapeutics, Inc. (NASDAQ:
BioXcel Therapeutics Inc. (NASDAQ:BTAI) Decline -10.90%, More Rally Possible 2021/12/02 15:30:00 Marketing Sentinel
In last trading session, BioXcel Therapeutics Inc. (NASDAQ:BTAI) saw 1.0 million shares changing hands with its beta currently measuring 0.94. Company’s recent per share price level of $20.43 trading at -$2.5 or -10.90% at ring of the bell on the day assigns it a market valuation of $561.62M. That closing price of BTAI’s stock is … BioXcel Therapeutics Inc. (NASDAQ:BTAI) Decline -10.90%, More Rally Possible Read More »
BioXcel Therapeutics (NASDAQ:BTAI) Shares Gap Down to $22.93 2021/12/01 16:02:42 Dakota Financial News
BioXcel Therapeutics, Inc. (NASDAQ:BTAI)s share price gapped down prior to trading on Wednesday . The stock had previously closed at $22.93, but opened at $17.31. BioXcel Therapeutics shares last traded at $19.91, with a volume of 3,915 shares trading hands. Several equities analysts have commented on the company. Berenberg Bank reiterated a buy rating and []